Navigation Links
Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company
Date:9/19/2012

OKLAHOMA CITY, Sept. 19, 2012 /PRNewswire/ -- Selexys Pharmaceuticals, Corp., announced today that it has successfully completed a $23 million Series A equity financing, led by MPM Capital.  Additionally, Selexys entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease.  Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $665 million.

The Series A financing includes a new major investor, MPM Capital. Concurrent with the investment, Selexys also announced the addition of Todd Foley, Managing Director of MPM Capital, to the Selexys Pharmaceuticals Board of Directors.

"Patients with sickle cell disease endure great suffering and frequent hospitalization due to painful vasoocclusive crises. Chronic blockade of P-selectin function with SelG1 may improve clinical outcomes and lower the associated cost of patient care," said Dr. Scott Rollins, President and CEO of Selexys. "We are excited to welcome MPM and Novartis and look forward to a productive partnership." The combination of the Novartis agreement and the closing of the Series A financing will allow Selexys to advance the SelG1 program through a large Phase 2 clinical study in sickle cell patients and will also fund a second program at Selexys, an anti-PSGL-1 antibody, through a Phase I clinical study.

"Vasoocculsive crises represent a significant healthcare problem for sickle cell disease patients, and we were impressed by the early data for SelG1 and the quality of the Selexys team," said Todd Foley, Managing Director of MPM Capital. "We are pleased to be a part of this successful financing structure, and I look forward to working closely with Selexys."

About SelG1

SelG1 is an investigatio
'/>"/>

SOURCE Selexys Pharmaceuticals, Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... MILPITAS, Calif. , July 10, 2014 ... a leader in advanced memory and analog IC solutions, ... call on Thursday, July 24, 2014, at 7:00 a.m. ... Company,s financial results for the fiscal 2014 third quarter ... conference call via telephone, dial 1-888-556-4997 before 6:50 a.m. ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:1/15/2014)... Sono-Tek Corporation (OTC BB: SOTK) today announced sales of  $2,650,000 ... sales of $2,202,000 for the prior year period, an increase ... shown growth over the preceding quarter,s sales, continuing a trend ... Markets that experienced sales increases over the prior year were ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... LAUREL, N.J., Dec. 1 MedQuist Inc. (Nasdaq: ... services, today announced that the radiology search tool from Primordial ... real-time speech recognition system. The solution is being demonstrated at ... through December 2. , Radiologists now have ...
... , ... Tianyin,Pharmaceutical Co., Inc., (NYSE Amex: TPI ), a ... in Chengdu, China, today,announced that it has received approvals ... produce Pediatric Fever and Cough Oral Liquid in,dosage form ...
Cached Medicine Technology:MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3
(Date:7/12/2014)... increase in the summer as people gather around fire pits, ... vulnerable to these seasonal fire hazards: children. "Young children ... putting their hands on the side of cooking grills," Dr. ... University Medical Center in Maywood, Ill., said in a Loyola ... with fire, you get burned, is true -- you ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP notes ... metal ion levels to the failure of metal-on-metal hip ... issue of The Journal of Bone & Joint Surgery, ... unilateral Articular Surface Replacement prostheses at least twelve months ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview ... health questions. Paddock tackles topics including main men's ... live longer than men, and testosterone replacement therapy, among ... featured on Doylestown Hospital’s website, Dr. Brad Paddock ... age. If you notice pain, bulging, or asymmetry in ...
(Date:7/12/2014)... 12, 2014 Praeclarus Press ... as a valuable new resource for women in need ... American women work away from their children. Today’s mothers ... benefits of breastfeeding, but often feel unsupported when it ... babies. With its evidence-based insights, and written by Nancy ...
(Date:7/12/2014)... July 12, 2014 The largest pure ... is pleased to announce that it will be opening ... new facility will join four Atlanta-based Nova Medical Centers’ ... at 3209 Deans Bridge Road, and will be open ... , “With Nova’s treatment philosophy of rapid return-to-work ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today ... upcoming SIGnificant Investment,Options in Healthcare Conference hosted by Susquehanna ... ET at the W Hotel in the Sea/Ocean,Room in ... only webcast of the company presentation,can be accessed under ...
... universal standards for new technology called IMRT , , TUESDAY, ... a highly refined, complex radiation treatment for killing tumors ... one medical center to the next than previously thought, ... a very large and serious problem for the radiation ...
... that stimulates blood vessel growth worsens ovarian cancer, but its ... wrapped in a fatty nanoparticle, a research team led by ... Center reports in the Journal of the National Cancer Institute. ... in ovarian cancer," said senior author Anil Sood, M.D., professor ...
... Coach Now Works to Help Hollywood ,Stay Sane in an Insane ... ... Rebecca Roy, M.A., "The,Industry Therapist" ( http://www.theIndustryTherapist.com ) is asking the,question ... than Britney Spears, mental illness., "Heath Ledger,s death is being treated ...
... HOLX ) today announced that Glenn Muir, Chief Financial ... 29th Annual,Institutional Investors Conference being held March 2-5, 2008 ... Interested parties are invited to listen to a ... 3, 2008 at 10:25 a.m.,Eastern Time on the investor ...
... blood clots, study says, , , TUESDAY, Feb. 26 (HealthDay ... symptoms associated with cancer treatment-related anemia may do more ... doses. , The drugs -- erythropoiesis-stimulating agents (ESAs) -- ... the risk of blood clots known as venous thromboembolisms ...
Cached Medicine News:Health News:Study Finds Variations in Doses of Radiation Therapy 2Health News:Study Finds Variations in Doses of Radiation Therapy 3Health News:Researchers identify and shut down protein that fuels ovarian cancer 2Health News:Researchers identify and shut down protein that fuels ovarian cancer 3Health News:Hologic to Present at the Raymond James & Associates 29th Annual Institutional Investors Conference 2Health News:Anemia Drugs for Cancer Patients Increase Death Risk 2Health News:Anemia Drugs for Cancer Patients Increase Death Risk 3
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Primary knee system, symmetrical in design....
Cruciate retaining, posterior stabilized and constrained components....
Maximum contact. Minimum wear. Outstanding results....
Medicine Products: